Stephanie Wallgren, Cristóbal S Berry-Cabán, Laura Bowers
{"title":"Impact of clinical pharmacist intervention on diabetes-related outcomes in a military treatment facility.","authors":"Stephanie Wallgren, Cristóbal S Berry-Cabán, Laura Bowers","doi":"10.1345/aph.1Q564","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clinical pharmacist management of patients with diabetes has been well justified, but there is a lack of research that evaluates the impact of pharmacist-managed diabetes care versus standard medical care on American Diabetes Association (ADA) treatment goals other than hemoglobin A(1c) (A1C).</p><p><strong>Objective: </strong>To evaluate the reduction in A1C, blood pressure, and low-density lipoprotein cholesterol (LDL-C) for patients with diabetes whose care was managed by a clinical pharmacist and compare these values to those of a cohort of patients whose care was managed by primary care providers. The difference in percentage of patients attaining ADA treatment goals between the 2 groups was also evaluated.</p><p><strong>Methods: </strong>This retrospective chart review identified 98 diabetic patients managed by a clinical pharmacist with at least 2 A1C measurements between September 15, 2008, and March 15, 2011. The Military Health System Population Health Portal was used to identify a similar group of patients with diabetes managed by their primary care provider (N = 90). The Armed Forces Health Longitudinal Technology Application was used to collect baseline data and the most recent measurements for A1C, blood pressure, LDL-C, and documented immunizations.</p><p><strong>Results: </strong>The pharmacist group saw positive improvements in all primary end points, including a 1.6% reduction in A1C, a 9-mm Hg and 1.4-mm Hg reduction in systolic and diastolic blood pressure, respectively, and a 16.3-mg/dL reduction in LDL-C. Conversely, the control group had an increase of 0.8% in A1C and 1.5 mm Hg in diastolic blood pressure. Reductions in systolic blood pressure and LDL-C were much less robust than in the pharmacist group (1.6 mm Hg and 5.2 mg/dL, respectively). Overall, patients in the pharmacist group were more likely to achieve ADA treatment goals.</p><p><strong>Conclusion: </strong>Pharmacist management of patients with diabetes significantly reduces A1C and allows more patients to meet ADA treatment goals. A clinical pharmacist-run diabetes clinic can provide numerous clinical benefits to patients.</p>","PeriodicalId":512049,"journal":{"name":"The Annals of pharmacotherapy","volume":" ","pages":"353-7"},"PeriodicalIF":0.0000,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1345/aph.1Q564","citationCount":"32","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Annals of pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1345/aph.1Q564","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/3/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 32
Abstract
Background: Clinical pharmacist management of patients with diabetes has been well justified, but there is a lack of research that evaluates the impact of pharmacist-managed diabetes care versus standard medical care on American Diabetes Association (ADA) treatment goals other than hemoglobin A(1c) (A1C).
Objective: To evaluate the reduction in A1C, blood pressure, and low-density lipoprotein cholesterol (LDL-C) for patients with diabetes whose care was managed by a clinical pharmacist and compare these values to those of a cohort of patients whose care was managed by primary care providers. The difference in percentage of patients attaining ADA treatment goals between the 2 groups was also evaluated.
Methods: This retrospective chart review identified 98 diabetic patients managed by a clinical pharmacist with at least 2 A1C measurements between September 15, 2008, and March 15, 2011. The Military Health System Population Health Portal was used to identify a similar group of patients with diabetes managed by their primary care provider (N = 90). The Armed Forces Health Longitudinal Technology Application was used to collect baseline data and the most recent measurements for A1C, blood pressure, LDL-C, and documented immunizations.
Results: The pharmacist group saw positive improvements in all primary end points, including a 1.6% reduction in A1C, a 9-mm Hg and 1.4-mm Hg reduction in systolic and diastolic blood pressure, respectively, and a 16.3-mg/dL reduction in LDL-C. Conversely, the control group had an increase of 0.8% in A1C and 1.5 mm Hg in diastolic blood pressure. Reductions in systolic blood pressure and LDL-C were much less robust than in the pharmacist group (1.6 mm Hg and 5.2 mg/dL, respectively). Overall, patients in the pharmacist group were more likely to achieve ADA treatment goals.
Conclusion: Pharmacist management of patients with diabetes significantly reduces A1C and allows more patients to meet ADA treatment goals. A clinical pharmacist-run diabetes clinic can provide numerous clinical benefits to patients.
背景:临床药师对糖尿病患者的管理已经得到了很好的证明,但缺乏评估药师管理的糖尿病护理与标准医疗护理对美国糖尿病协会(ADA)治疗目标的影响的研究,而不是血红蛋白a (1c) (A1C)。目的:评估由临床药师管理的糖尿病患者的糖化血红蛋白、血压和低密度脂蛋白胆固醇(LDL-C)的降低,并将这些值与由初级保健提供者管理的一组患者的值进行比较。两组患者达到ADA治疗目标的百分比差异也进行了评估。方法:本回顾性图表研究确定了2008年9月15日至2011年3月15日期间由临床药剂师管理的至少有2项A1C测量的98例糖尿病患者。使用军队卫生系统人口健康门户网站来确定由其初级保健提供者管理的类似糖尿病患者组(N = 90)。使用武装部队健康纵向技术应用程序收集基线数据和A1C、血压、LDL-C的最新测量结果,并记录免疫接种情况。结果:药剂师组在所有主要终点都有积极的改善,包括A1C降低1.6%,收缩压和舒张压分别降低9毫米汞柱和1.4毫米汞柱,LDL-C降低16.3毫克/分升。相反,对照组的糖化血红蛋白升高0.8%,舒张压升高1.5 mm Hg。收缩压和LDL-C的降低远不如药剂师组(分别为1.6 mm Hg和5.2 mg/dL)。总体而言,药剂师组的患者更有可能实现ADA的治疗目标。结论:药师管理糖尿病患者可显著降低糖化血红蛋白,使更多患者达到ADA治疗目标。临床药师经营的糖尿病诊所可以为患者提供许多临床益处。